Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial

Koorosh Korfi, Ailsa Christiansen, Zhiwen Jiang, Sabine Wilson, Samuel Tracy, Annika Blank, Sylvia Herter, Natalie Dimier, Bruno Gomes, Pablo Umana, Herve Ghesquieres, Roch Houot, Fritz Offner, Harriet Walter, Nancy L. Bartlett, Guillaume Cartron, Michael Dickinson, William Townsend, Giuseppe Gritti, Francesc Bosch Albareda, Franck Morschhauser, Martin Hutchings, Carmelo Carlo-Stella, Katharina Lechner

Open source

DOI: 10.1182/blood-2023-173677
Published: 2023-11-02
Container: Blood
Publisher: American Society of Hematology
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/blood-2023-173677,
  title = {Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial},
  author = {Koorosh Korfi and Ailsa Christiansen and Zhiwen Jiang and Sabine Wilson and Samuel Tracy and Annika Blank and Sylvia Herter and Natalie Dimier and Bruno Gomes and Pablo Umana and Herve Ghesquieres and Roch Houot and Fritz Offner and Harriet Walter and Nancy L. Bartlett and Guillaume Cartron and Michael Dickinson and William Townsend and Giuseppe Gritti and Francesc Bosch Albareda and Franck Morschhauser and Martin Hutchings and Carmelo Carlo-Stella and Katharina Lechner},
  year = {2023},
  journal = {Blood},
  doi = {10.1182/blood-2023-173677},
  url = {https://doi.org/10.1182/blood-2023-173677}
}

RIS

TY  - JOUR
TI  - Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial
AU  - Koorosh Korfi
AU  - Ailsa Christiansen
AU  - Zhiwen Jiang
AU  - Sabine Wilson
AU  - Samuel Tracy
AU  - Annika Blank
AU  - Sylvia Herter
AU  - Natalie Dimier
AU  - Bruno Gomes
AU  - Pablo Umana
AU  - Herve Ghesquieres
AU  - Roch Houot
AU  - Fritz Offner
AU  - Harriet Walter
AU  - Nancy L. Bartlett
AU  - Guillaume Cartron
AU  - Michael Dickinson
AU  - William Townsend
AU  - Giuseppe Gritti
AU  - Francesc Bosch Albareda
AU  - Franck Morschhauser
AU  - Martin Hutchings
AU  - Carmelo Carlo-Stella
AU  - Katharina Lechner
PY  - 2023
JO  - Blood
DO  - 10.1182/blood-2023-173677
UR  - https://doi.org/10.1182/blood-2023-173677
ER  -

APA

Korfi, K., Christiansen, A., Jiang, Z., Wilson, S., Tracy, S., Blank, A., Herter, S., Dimier, N., Gomes, B., Umana, P., Ghesquieres, H., Houot, R., Offner, F., Walter, H., Bartlett, N. L., Cartron, G., Dickinson, M., Townsend, W., Gritti, G., Albareda, F. B., Morschhauser, F., Hutchings, M., Carlo-Stella, C., & Lechner, K. (2023). Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial. Blood. https://doi.org/10.1182/blood-2023-173677

Source records

crossref · retrieved 2026-09-26T05:12:13.984Z